Walvax BioTech Net Assets
Walvax BioTech net assets. Based on the latest financial reports, Walvax BioTech (300142) has net assets worth CN¥7.33 Billion CNY (≈ $1.07 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥10.50 Billion ≈ $1.54 Billion USD) and total liabilities (CN¥3.17 Billion ≈ $463.69 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See Walvax BioTech (300142) net asset quality to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥7.33 Billion |
| % of Total Assets | 69.82% |
| Annual Growth Rate | 42.06% |
| 5-Year Change | -1.86% |
| 10-Year Change | 178.5% |
| Growth Volatility | 319.44 |
Net Assets of Walvax BioTech (2007–2025)
Net assets of Walvax BioTech from 2007 to 2025. This chart illustrates how Walvax BioTech's net assets have evolved over time, based on quarterly financial data. Also explore how fast is Walvax BioTech growing its equity to track the company's year-over-year net asset growth rate.
Annual Net Assets for Walvax BioTech (2007–2025)
The table below shows the annual net assets of Walvax BioTech from 2007 to 2025. For live market cap and overall valuation, see how much is Walvax BioTech worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥9.81 Billion ≈ $1.44 Billion |
-14.73% |
| 2024-12-31 | CN¥11.51 Billion ≈ $1.68 Billion |
+0.99% |
| 2023-12-31 | CN¥11.40 Billion ≈ $1.67 Billion |
+3.69% |
| 2022-12-31 | CN¥10.99 Billion ≈ $1.61 Billion |
+9.91% |
| 2021-12-31 | CN¥10.00 Billion ≈ $1.46 Billion |
+27.41% |
| 2020-12-31 | CN¥7.85 Billion ≈ $1.15 Billion |
+38.51% |
| 2019-12-31 | CN¥5.67 Billion ≈ $829.11 Million |
+7.67% |
| 2018-12-31 | CN¥5.26 Billion ≈ $770.02 Million |
+47.92% |
| 2017-12-31 | CN¥3.56 Billion ≈ $520.57 Million |
+0.96% |
| 2016-12-31 | CN¥3.52 Billion ≈ $515.62 Million |
+16.53% |
| 2015-12-31 | CN¥3.02 Billion ≈ $442.47 Million |
-5.86% |
| 2014-12-31 | CN¥3.21 Billion ≈ $470.01 Million |
+9.31% |
| 2013-12-31 | CN¥2.94 Billion ≈ $429.99 Million |
-7.29% |
| 2012-12-31 | CN¥3.17 Billion ≈ $463.81 Million |
+16.81% |
| 2011-12-31 | CN¥2.71 Billion ≈ $397.06 Million |
+6.37% |
| 2010-12-31 | CN¥2.55 Billion ≈ $373.28 Million |
+1360.26% |
| 2009-12-31 | CN¥174.69 Million ≈ $25.56 Million |
+77.61% |
| 2008-12-31 | CN¥98.36 Million ≈ $14.39 Million |
+457.06% |
| 2007-12-31 | CN¥17.66 Million ≈ $2.58 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Walvax BioTech's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 44657.5% over the analyzed period, indicating profitable operations and earnings retention.
Walvax BioTech Net Assets Breakdown (December 2025)
Walvax BioTech net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.86 Billion | 33.21% |
| Common Stock | CN¥1.60 Billion | 18.55% |
| Other Comprehensive Income | CN¥1.22 Billion | 14.19% |
| Other Components | CN¥2.94 Billion | 34.05% |
| Total Equity | CN¥8.62 Billion | 100.00% |
Walvax BioTech Competitors by Market Cap
The table below lists competitors of Walvax BioTech ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lerøy Seafood Group ASA
OL:LSG
|
$2.69 Billion |
|
Braze Inc
NASDAQ:BRZE
|
$2.69 Billion |
|
Lagardere SCA
PA:MMB
|
$2.69 Billion |
|
Xiamen Bank Co Ltd
SHG:601187
|
$2.70 Billion |
|
CCC S.A.
WAR:CCC
|
$2.69 Billion |
|
ArcBest Corp
NASDAQ:ARCB
|
$2.69 Billion |
|
Ta Liang Technology Co Ltd
TW:3167
|
$2.69 Billion |
|
Gold Road Resources Ltd
AU:GOR
|
$2.69 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Walvax BioTech's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 9,429,543,133 to 8,620,990,550, a change of -808,552,583 (-8.6%).
- Net income of 177,741,534 contributed positively to equity growth.
- Dividend payments of 28,993,834 reduced retained earnings.
- Other comprehensive income increased equity by 1,223,516,231.
- Other factors decreased equity by 2,180,816,514.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥177.74 Million | +2.06% |
| Dividends Paid | CN¥28.99 Million | -0.34% |
| Other Comprehensive Income | CN¥1.22 Billion | +14.19% |
| Other Changes | CN¥-2.18 Billion | -25.3% |
| Total Change | CN¥- | -8.57% |
Book Value vs Market Value Analysis
This analysis compares Walvax BioTech's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 61.22x to 2.14x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.19 | CN¥11.51 | x |
| 2008-12-31 | CN¥0.16 | CN¥11.51 | x |
| 2009-12-31 | CN¥0.17 | CN¥11.51 | x |
| 2010-12-31 | CN¥2.09 | CN¥11.51 | x |
| 2011-12-31 | CN¥1.93 | CN¥11.51 | x |
| 2012-12-31 | CN¥2.10 | CN¥11.51 | x |
| 2013-12-31 | CN¥1.91 | CN¥11.51 | x |
| 2014-12-31 | CN¥2.01 | CN¥11.51 | x |
| 2015-12-31 | CN¥1.63 | CN¥11.51 | x |
| 2016-12-31 | CN¥2.28 | CN¥11.51 | x |
| 2017-12-31 | CN¥1.97 | CN¥11.51 | x |
| 2018-12-31 | CN¥2.98 | CN¥11.51 | x |
| 2019-12-31 | CN¥3.16 | CN¥11.51 | x |
| 2020-12-31 | CN¥4.23 | CN¥11.51 | x |
| 2021-12-31 | CN¥5.30 | CN¥11.51 | x |
| 2022-12-31 | CN¥5.66 | CN¥11.51 | x |
| 2023-12-31 | CN¥5.84 | CN¥11.51 | x |
| 2024-12-31 | CN¥5.90 | CN¥11.51 | x |
| 2025-12-31 | CN¥5.39 | CN¥11.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Walvax BioTech utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.37%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.40x
- Recent ROE (2.06%) is below the historical average (8.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 42.05% | 5.74% | 0.59x | 12.32x | CN¥5.66 Million |
| 2008 | 35.28% | 18.85% | 0.61x | 3.07x | CN¥24.86 Million |
| 2009 | 43.70% | 31.92% | 0.62x | 2.21x | CN¥58.86 Million |
| 2010 | 6.05% | 43.04% | 0.12x | 1.17x | CN¥-100.67 Million |
| 2011 | 7.65% | 44.14% | 0.16x | 1.11x | CN¥-63.81 Million |
| 2012 | 7.88% | 43.31% | 0.12x | 1.51x | CN¥-62.61 Million |
| 2013 | 1.75% | 8.21% | 0.10x | 2.24x | CN¥-226.36 Million |
| 2014 | 4.98% | 19.95% | 0.12x | 2.07x | CN¥-144.87 Million |
| 2015 | -36.81% | -83.59% | 0.16x | 2.74x | CN¥-1.07 Billion |
| 2016 | 2.20% | 11.92% | 0.09x | 1.97x | CN¥-250.27 Million |
| 2017 | -17.74% | -80.38% | 0.11x | 1.94x | CN¥-839.87 Million |
| 2018 | 22.84% | 119.66% | 0.12x | 1.58x | CN¥588.21 Million |
| 2019 | 2.92% | 12.66% | 0.16x | 1.44x | CN¥-344.54 Million |
| 2020 | 15.33% | 34.13% | 0.30x | 1.47x | CN¥348.71 Million |
| 2021 | 5.04% | 12.35% | 0.25x | 1.61x | CN¥-420.68 Million |
| 2022 | 8.02% | 14.33% | 0.33x | 1.69x | CN¥-179.75 Million |
| 2023 | 4.49% | 10.19% | 0.26x | 1.67x | CN¥-515.54 Million |
| 2024 | 1.51% | 5.04% | 0.19x | 1.56x | CN¥-800.79 Million |
| 2025 | 2.06% | 7.37% | 0.20x | 1.40x | CN¥-684.36 Million |
Industry Comparison
This section compares Walvax BioTech's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $7,692,779,830
- Average return on equity (ROE) among peers: 10.83%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Walvax BioTech (300142) | CN¥7.33 Billion | 42.05% | 0.43x | $2.69 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $57.63 Million | 31.51% | 1.53x | $488.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.56 Billion | 7.90% | 1.45x | $358.35 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $366.91 Million | 9.97% | 0.26x | $4.46 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $11.75 Billion | 9.21% | 0.48x | $2.38 Billion |
| Wedge Industrial Co Ltd (000534) | $596.67 Million | 0.77% | 0.03x | $1.24 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.87 Billion | 12.22% | 0.36x | $13.82 Billion |
| Hainan Haiyao Co Ltd (000566) | $317.39 Million | 7.74% | 0.74x | $747.99 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $65.32 Million | 20.59% | 1.16x | $281.39 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $905.53 Million | 2.15% | 1.95x | $904.12 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $22.44 Billion | 6.25% | 0.15x | $2.87 Billion |
About Walvax BioTech
Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China and internationally. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, grou… Read more